摘要
急性髓系白血病(AML)是一种异质性血液系统恶性肿瘤。近年来,随着各种生物学技术,如流式细胞术、分子生物学、质谱等的飞速发展及应用,人们对于AML的发病机制有了更深入的认识,世界卫生组织多次更新了AML的疾病诊断分类,欧洲白血病网也修订了AML的遗传危险度分层建议。与此同时,针对AML患者治疗后可检测残留病的监测、治疗方案的分层设计及分子靶向药物与免疫治疗的应用也取得了长足的进步,AML进入了更加精准的诊治时代。
Acute myeloid leukemia(AML)is a heterogeneous hematological malignancy.In recent years,with the rapid development and application of various biological techniques,such as flow cytometry,molecular biology and mass spectrometry,people have a deeper understanding of the pathogenesis of AML.The World Health Organization has updated the diagnostic classification of AML several times,and the European Leukemia Network has revised the recommendations for genetic risk stratification of AML.At the same time,great progress has been made in the monitoring of measurable residual disease after treatment,the hierarchical design of treatment regimens,and the application of molecular targeted drugs and immunotherapy.AML has entered the era of more precise diagnosis and treatment.
作者
郑金娥
薛维
杜雯
黄士昂
Zheng Jin'e;Xue Wei;Du Wen;Huang Shiang(Center for Stem Cell Research,Institute of Hematology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China;Wuhan Kindstar Diagnostics Company Limited,Wuhan 430000,China)
出处
《巴楚医学》
2025年第1期1-11,共11页
Bachu Medical Journal
基金
浙江省科学技术厅应急攻关项目(2022C03189)。
关键词
急性髓系白血病
精准诊治
危险度分层
可检测残留病
分子靶向药物
acute myeloid leukemia(AML)
precise diagnosis and treatment
risk stratification
measurable residual disease
molecular targeted drugs
